MONOPAR THERAPEUTICS INC
NASDAQ: MNPR (Monopar Therapeutics Inc.)
Kemas kini terakhir: 4 minit lalu55.54
-0.73 (-1.29%)
| Penutupan Terdahulu | 56.26 |
| Buka | 55.93 |
| Jumlah Dagangan | 106,221 |
| Purata Dagangan (3B) | 274,813 |
| Modal Pasaran | 371,117,312 |
| Harga / Buku (P/B) | 2.61 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Mar 2026 |
| EPS Cair (TTM) | -3.98 |
| Nisbah Semasa (MRQ) | 36.92 |
| Aliran Tunai Operasi (OCF TTM) | -10.41 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -9.22 M |
| Pulangan Atas Aset (ROA TTM) | -34.49% |
| Pulangan Atas Ekuiti (ROE TTM) | -54.27% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Monopar Therapeutics Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -5.0 |
| Purata | 0.13 |
|
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 34.38% |
| % Dimiliki oleh Institusi | 47.24% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 115.00 (Morgan Stanley, 107.08%) | Beli |
| Median | 104.00 (87.27%) | |
| Rendah | 100.00 (Chardan Capital, 80.07%) | Beli |
| Purata | 106.33 (91.47%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 62.05 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 23 Feb 2026 | 104.00 (87.27%) | Beli | 55.80 |
| 02 Feb 2026 | 104.00 (87.27%) | Beli | 65.48 | |
| Chardan Capital | 29 Jan 2026 | 100.00 (80.07%) | Beli | 67.34 |
| Morgan Stanley | 09 Jan 2026 | 115.00 (107.08%) | Beli | 63.00 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |